Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | CCR9 | P51686 | 16/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CCR2 | P41597 | 1/20 | 0.52 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.51 |
| ▸ | SLC10A6 | Q3KNW5 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29077 | 0.92 | LMNA (0.65) | LMNAHTTCCR9TP53MAPT | |
| SCHEMBL27848 | 0.89 | LMNA (0.68) | LMNAHTTCCR9TP53MAPT | |
| SCHEMBL27982 | 0.88 | LMNA (0.77) | LMNAHTTCCR9TP53MAPT | |
| SCHEMBL14475386 | 0.86 | BDKRB1 (0.56) | LMNAHTTCCR9TP53MAPT | |
| SCHEMBL13138224 | 0.84 | LMNA (0.65) | LMNAHTTCCR9TP53MAPT | |
| SCHEMBL12032413 | 0.83 | CCR9 (0.82) | LMNAHTTCCR9TP53MAPT | |
| SCHEMBL27344 | 0.82 | CCR9 (0.78) | LMNAHTTCCR9TP53MAPT | |
| SCHEMBL19860941 | 0.81 | CCR9 (0.78) | LMNAHTTCCR9TP53MAPT | |
| SCHEMBL27758 | 0.80 | LMNA (0.78) | LMNAHTTCCR9TP53MAPT | |
| SCHEMBL28642 | 0.80 | LMNA (0.74) | LMNAHTTCCR9TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999109-B2 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100093802-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNNIUM PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-7659272-B2 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093802-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | CCR9, CCR1, CCR4 | LMNA 3548/4885HTT 4358/4885CCR9 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.